Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Masked hypertension and elevated nighttime BP are associated with increased risk of hypertensive target organ damage and adverse cardiovascular and renal outcomes in patients with normal kidney function. The significance of masked hypertension for these risks in patients with CKD is less well defined. The objective of this study was to evaluate the association between masked hypertension and kidney function and markers of cardiovascular target organ damage, and to determine whether this relationship was consistent among those with and without elevated nighttime BP. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a cross-sectional study. We performed 24-hour ambulatory BP in 1492 men and women with CKD enrolled in the Chronic Renal Insufficiency Cohort Study. We categorized participants into controlled BP, white-coat, masked, and sustained hypertension on the basis of clinic and 24-hour ambulatory BP. We obtained echocardiograms and measured pulse wave velocity in 1278 and 1394 participants, respectively. RESULTS: The percentages of participants with controlled BP, white-coat, masked, and sustained hypertension were 49.3%, 4.1%, 27.8%, and 18.8%, respectively. Compared with controlled BP, masked hypertension independently associated with low eGFR (-3.2 ml/min per 1.73 m(2); 95% confidence interval, -5.5 to -0.9), higher proteinuria (+0.9 unit higher in log2 urine protein; 95% confidence interval, 0.7 to 1.1), and higher left ventricular mass index (+2.52 g/m(2.7); 95% confidence interval, 0.9 to 4.1), and pulse wave velocity (+0.92 m/s; 95% confidence interval, 0.5 to 1.3). Participants with masked hypertension had lower eGFR only in the presence of elevated nighttime BP (-3.6 ml/min per 1.73 m(2); 95% confidence interval, -6.1 to -1.1; versus -1.4 ml/min per 1.73 m(2); 95% confidence interval, -6.9 to 4.0, among those with nighttime BP <120/70 mmHg; P value for interaction with nighttime systolic BP 0.002). CONCLUSIONS: Masked hypertension is common in patients with CKD and associated with lower eGFR, proteinuria, and cardiovascular target organ damage. In patients with CKD, ambulatory BP characterizes the relationship between BP and target organ damage better than BP measured in the clinic alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A lower eGFR is associated with resistant hypertension, masked hypertension, and elevated nighttime BP values. 92”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypertension is a major risk factor for the development and progression of albuminuria and any form of CKD. 92”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [92]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Self-citationLang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
O'Brien, E., Asmar, R., Beilin, L., Imai, Y., Mallion, J.-M., Mancia, G., Mengden, T., Myers, M., Padfield, P., Palatini, P., et al. (2003) · Journal of Hypertension · doi:10.1097/00004872-200305000-00001 · Cited by 1,655
Vlachopoulos, C., Aznaouridis, K., O'Rourke, M. F., Safar, M. E., Baou, K., & Stefanadis, C. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq024 · Cited by 1,363
Bobrie, G. (2004) · JAMA · doi:10.1001/jama.291.11.1342 · Cited by 842
Impact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barre, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 784
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods
Feldman, H. I., Appel, L. J., Chertow, G. M., Cifelli, D., Cizman, B., Daugirdas, J., Fink, J. C., Franklin-Becker, E. D., Go, A. S., Hamm, L. L., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000070149.78399.ce · Cited by 659
Self-citationLash, J. P., Go, A. S., Appel, L. J., He, J., Ojo, A., Rahman, M., Townsend, R. R., Xie, D., Cifelli, D., Cohan, J., et al. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00070109 · Cited by 619
Self-citationAortic pulse wave velocity index and mortality in end-stage renal disease
Blacher, J., Safar, M. E., Guerin, A. P., Pannier, B., Marchais, S. J., & London, G. M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00932.x · Cited by 532
Cited by
Items 101–198 of 198
Masked uncontrolled hypertension in patients on maintenance hemodialysis
Liu, W., Wang, L., Sun, Z., Li, X., Zhou, J., Gao, C., Chu, H., Fan, W., Bai, Y., & Yang, J. (2017) · Hypertension Research · doi:10.1038/hr.2017.48 · Cited by 9
Kasper, P., Nhlema, A., de Forest, A., Tweya, H. M., Chaweza, T., Mwagomba, B. M., Muula, A., Chiwoko, J., Neuhann, F., Phiri, S., et al. (2021) · Global Heart · doi:10.5334/gh.945 · Cited by 8
Smith, J. R., Hillman, L. A., & Drawz, P. E. (2017) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2017.1411493 · Cited by 8
“Additionally, nighttime blood pressure is elevated in patients with CKD and proteinuria (7).”
BackgroundSelf-citationHypertension Management in Chronic Kidney Disease and Diabetes
Thomas, G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.04.006 · Cited by 11
Syme, H. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-33020-0_3 · Cited by 10
Thomas, G., Felts, J., Brecklin, C. S., Chen, J., Drawz, P. E., Lustigova, E., Mehta, R. C., Miller, E. R., Sozio, S. M., Weir, M. R., et al. (2020) · Kidney360 · doi:10.34067/kid.0002072020 · Cited by 8
Self-citationPrevalence and factors associated with masked hypertension in chronic kidney disease
Legrand, F., Motiejūnaitė, J., Arnoult, F., Lahens, A., Tabibzadeh, N., Robert, T., Rouzet, F., de Pinho, N. A., Vrtovsnik, F., Flamant, M., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003680 · Cited by 8
Wirtwein, M., Melander, O., Sjögren, M., Hoffmann, M., Narkiewicz, K., Gruchała, M., & Sobiczewski, W. (2017) · Hypertension Research · doi:10.1038/hr.2017.87 · Cited by 8
Eşme, M., Asıl, S., Yavuz, B., Balcı, C., Kılıç, M. K., Kızılarslanoğlu, M. C., Varan, H. D., Doğrul, R. T., Halil, M. G., Cankurtaran, M., et al. (2019) · Blood Pressure · doi:10.1080/08037051.2019.1675475 · Cited by 7
“In another study examining the effects of MH in chronic kidney disease, MH was found to be associated with proteinuria [12].”
BackgroundAlsalloum, M. A., Albekery, M. A., & Alhomoud, I. S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1630160 · Cited by 12
Zhang, J., Song, J., Zhou, L., Zhou, W., Rao, J., Li, Y., Wu, J., Peng, H., & Lou, T. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002930 · Cited by 6
“The CRIC study, which enrolled 1492 CKD participants, explained the relationship between ambulatory BP and TOD [25].”
MethodWang, Q., Wang, Y., Wang, J., Zhang, L., Zhao, M., (C-STRIDE), T. C. C. S. O. C. K. D., Zhao, M., Zhang, L., Wang, X., Yuan, J., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02447-0 · Cited by 6
Prognostic value of nighttime blood pressure in patients with chronic kidney disease
Li, J., Qin, W. D., Li, S., Song, J., Wang, C., Zhang, J., & Peng, H. (2025) · Hypertension Research · doi:10.1038/s41440-024-02080-0 · Cited by 5
“Ambulatory blood pressure (ABP) measurement has shown a stronger association with the prognosis of CKD than of fi ce blood pressure (BP) measurement [5]; therefore, current guidelines recommend ABP monitoring for BP These authors contributed equally: Jiawen Li, Qin Wei. assessment [6 – 8].”
Stróżecki, P., Pluta, A., Donderski, R. Ł., Włodarczyk, Z., & Manitius, J. (2020) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000499 · Cited by 7
Sorato, M. M., Davari, M., Kebriaeezadeh, A., Sarrafzadegan, N., & Shibru, T. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-022-00516-7 · Cited by 7
“%) of patients had CKD (Table 3 and Fig.”
BackgroundInfluentialSheng, C., Wang, D., Yuan, J., Cheng, Y., Sun, S., Yang, Y., Miao, Y., Wang, W., Tian, J., & Bloomgarden, Z. T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.977938 · Cited by 5
Masked hypertension and chronic kidney disease: the role of out-of-office blood pressure monitoring
Parati, G., Ochoa, J. E., & Stergiou, G. S. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001781 · Cited by 5
“Such a prevalence is by far higher than that reported for general populations and is even higher than the masked hypertension prevalence reported for African Americans with established CKD in previous studies, in spite of the fact that prevalence of masked hypertension is known to be higher in CKD patients [22,25].”
ResultPrediction of Masked Uncontrolled Hypertension Detected by Ambulatory Blood Pressure Monitoring
Coccina, F., Borrelli, P., Pierdomenico, A. M., Pizzicannella, J., Guagnano, M. T., Cuccurullo, C., Nicola, M. D., Renda, G., Trubiani, O., Cipollone, F., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12123156 · Cited by 6
“Second, as the prevalence of chronic kidney disease tended to be low and that of diabetes was low in our population, the results cannot be extrapolated to populations of patients with chronic kidney disease [43] or diabetes mellitus [14].”
Mahmud, A., Alahaideb, R., Alshammary, H., Abanumay, M., Alfawwaz, A., Alhelabi, S., Alonazy, A., & Al‐Zaibag, M. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14059 · Cited by 4
Akbay, E., Çoner, A., Akıncı, S., Demir, A. R., & Toktamiş, A. (2021) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2021.1916946 · Cited by 7
“The increase in LVMI has often been demonstrated in MH studies and is a sign of target organ damage (9,10,27).”
BackgroundByfield, R. L., Zhang, R., Cohen, D. L., Townsend, R. R., Hossain, A., Shimbo, D., Cohen, J. B., CRIC Study Investigators, Anderson, A. H., Appel, L. J., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf102 · Cited by 6
Self-citationÁlvarez-Aliaga, A., Guerra, A. F., Quesada, A. S., Llano-Sosa, D. D., Saumell, J. B., & Santiesteban, Y. A. L. (2020) · Medwave · doi:10.5867/medwave.2020.03.7873 · Cited by 6
de Moura, E. L., Ferreira, J. M., dos Santos, A. C. M., da Silva, D. M., da Silva, M. L. F., Silva, G. K. M. D. O., Silva, P. H. N., dos Santos, J. A., Barbosa, M. A. D. S., Neto, A. B. L., et al. (2021) · Research Society and Development · doi:10.33448/rsd-v10i2.12533 · Cited by 5
“Third, chronic kidney disease leads to a series of complications, such as high blood pressure, anemia, water retention and these complications may have a greater effect on SARS-CoV-2 infection (Babitt & Lin, 2012; Drawz et al., 2016).”
BackgroundPalomo‐Piñón, S., Enciso‐Muñoz, J. M., Meaney, E., Díaz-Domínguez, E., Cardona‐Müller, D., Pérez, F. P., Cantoral-Farfán, E., Anda‐Garay, J. C., Mijangos-Chavez, J., Antonio‐Villa, N. E., et al. (2024) · BMC Nephrology · doi:10.1186/s12882-023-03450-5 · Cited by 9
“In a cohort of 1,219 patients living with CKD, high BP was independently correlated with organ damage [53]; similarly, Drawz et al., also demonstrated in a cohort of 1,492 patients with CKD an independent association between masked systemic arterial hypertension and end-organ damage [54].”
BackgroundTanaka, F., Komi, R., Nakamura, M., Tanno, K., Onoda, T., Ohsawa, M., Sakata, K., Omama, S., Ogasawara, K., Ishibashi, Y., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002394 · Cited by 4
White Coat and Masked Hypertension
Cuspidi, C., Sala, C., Tadić, M., & Grassi, G. M. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-59918-2_35 · Cited by 4
de la Fuente, G. D. A., del Valle, K. M. P., Tocora, D. G. G., & Rodríguez-Puyol, D. (2019) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2019.06.001 · Cited by 3
Impact of intensive blood pressure control on kidney outcomes
Huang, J. X., Peschard, V.-G., & Ku, E. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001070 · Cited by 3
“Finally, most adult trials have targeted clinic BP rather than ambulatory BP measurements despite evidence that masked hypertension is strongly prognostic of adverse kidney outcomes in observational studies, aside from HALT Progression of Polycystic Kidney Disease (HALT-PKD) [19,20].”
The role of clinic blood pressure for the diagnosis of hypertension
Ayan, M., Kadavath, S. M., & Campbell, P. T. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000528 · Cited by 3
Hypertension and Cardiovascular Disease in Patients with Chronic Kidney Disease
Hamrahian, S. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-83082-3_15 · Cited by 6
Gupta, A., Chouhdry, H., Ellis, S. D., Young, K. J., Mahnken, J. D., Comfort, B. W., Shanks, D., McGreevy, S., Rudy, C., Zufer, T., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107466 · Cited by 3
Masked phenomenon: renal and cardiovascular complications; review and updates
Habas, E. M., Errayes, A., Habas, E., Alfitori, G. B., Habas, A. M., Farfar, K., Rayani, A., Habas, A., & Elzouki, A.-N. Y. (2024) · Blood Pressure · doi:10.1080/08037051.2024.2383234 · Cited by 3
“MHTN is associated with a higher rate of negative hypertensive renal outcomes in individuals with normal kidney function [11].”
InfluentialMasked arterial hypertension: what is known and what expected to be learned?
Gorshkov, A. Y., Александрович, Ф. А., & Drapkina, O. M. (2020) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202023062143 · Cited by 4
Pasricha, S. V., Cohen, D. L., Shulman, R., Byfield, R. L., Cohen, J. B., CRIC Study Investigators, Anderson, A. H., Appel, L. J., Chen, J., Cohen, D. L., et al. (2026) · Journal of Human Hypertension · doi:10.1038/s41371-026-01166-1 · Cited by 3
“However, statistical power would be limited in this approach given the plethora of combination regimens, so we chose the advantageous approach of a multinomial regression with penalized p -values.”
Self-citationAslam, N., Missick, S., & Haley, W. E. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.02.001 · Cited by 3
Aortic arch calcification: a novel parameter for prediction of masked hypertension
Akbay, E., Çoner, A., Akıncı, S., Adar, A., Çakan, F., & Müderrisoğlu, H. (2021) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000529 · Cited by 3
Chotruangnapa, C., Thammarux, T., & Thongdang, P. (2022) · International Journal of Hypertension · doi:10.1155/2022/6912839 · Cited by 3
“Masked uncontrolled hypertension was also common in patients with chronic kidney disease and reduced glomerular fltration rate [27, 28].”
BackgroundBinding, C., Elmegaard, M., Zahir, D., Carlson, N., Schou, M., & Bonde, A. N. (2025) · Open Heart · doi:10.1136/openhrt-2025-003270 · Cited by 7
Cohen, J. B., & Townsend, R. R. (2020) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2020.19.1.2 · Cited by 2
Self-citationMera-Gallego, I., Tous, S., Más, R. P., Molinero, A., Fornos-Pérez, J. A., & Rodríguez, N. F. A. (2023) · Farmacéuticos Comunitarios · doi:10.33620/fc.2173-9218.(2023).27 · Cited by 2
Management of Hypertension in Chronic Kidney Disease
Rahman, M., Drawz, P. E., Thomas, G., & Turner, J. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00061-9 · Cited by 2
Self-citationHypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?
Katsimardou, A., Stavropoulos, K., Imprialos, K. P., Doumas, M. N., & Athyros, V. G. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13676 · Cited by 2
Blood pressure control in hypertensive patients with chronic kidney disease
Kawada, T. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001328 · Cited by 2
Hypertension in patients with CKD in China: clinical characteristics and management
Cai, G., & Chen, X. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0578-8 · Cited by 2
Giordano, J., Battle, S. J., Edwards, E. W., & DiPette, D. J. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14167 · Cited by 2
Lan, S., Zhang, Y., Wang, J., Wu, Z., & Chen, S. (2023) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000661 · Cited by 1
dos Santos, R. B., Silva, G. F., Drager, L. F., & Pio-Abreu, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082663 · Cited by 1
“In addition, current studies demonstrated that the MUCH phenotype has worse outcomes related to target organ damage (TOD) compared to controlled hypertension (CH) patients, including reduced eGFR, increased albuminuria, vascular stiffness, and left ventricular hypertrophy (LVH) [9,13–16].”
Abdallah, S., Saddik, G. E., Bahous, S. A., Kilani, H., Kallab, S., & Hassan, H. I. C. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.048285 · Cited by 1
Chang, T. I., Cluett, J., Cohen, D. L., Drawz, P. E., Hudson, J. Q., Kramer, H., Rahman, M., & Awdishu, L. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.07.006 · Cited by 1
Self-citationHypertension and Sudden Cardiac Death
Shenasa, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-39599-9_18 · Cited by 2
How common is Balkan endemic nephropathy among immigrants in endemic regions?
Đukanović, L., Račić, M., Marić, I., Maksimović, Z., Simić, J., Aleksić, J., Stankovic, S. D., Pejović, V., & Ležaić, V. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-1889-7 · Cited by 1
Труханова, М. А., Orlov, A. V., Tolkacheva, V. V., Троицкая, Е. А., Вадимовна, В. С., & Kobalava, Z. D. (2019) · Kardiologiia · doi:10.18087/cardio.2681 · Cited by 1
“СМАД позволяет выявить ночную АГ – более значимый предиктор сердечнососудистых осложнений, чем дневное АД [19].”
Goldman, J. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-83082-3_7 · Cited by 1
Renal and Heart Failure Interrelationship in Hypertension
Redón, J. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-39315-0_9 · Cited by 1
SHELKE, K., Parkhe, T. S., & SHINDE, D. (2025) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2025v17i8.54827 · Cited by 1
Fixed combinations in modern hypertension treatment algorithms
Sayutina, E. V. (2018) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2018-6-86-94 · Cited by 1
Hypertension: A Common but Complex Condition
Umanath, K. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.03.019 · Cited by 2
Blood Pressure: The Interactions Between Hypertension and Kidney Disease
Rayner, H. C., Thomas, M. E., & Milford, D. V. (2020) · Springer eBooks · doi:10.1007/978-3-030-43027-6_11 · Cited by 1
Kim, Y., Kim, J., Lee, S. W., Sung, S. A., Yoo, T., Lee, K., Hwang, Y., Kim, T. H., Kang, S. W., Kim, Y. H., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002624 · Cited by 1
“studies, masked hypertension and nondipping pattern were associated with lower estimated glomerular filtration rate (eGFR), higher proteinuria and higher left ventricular mass index [7,8,10].”
BackgroundSignificance of ambulatory blood pressure monitoring in assessment of potential living kidney donors
Ahmed, A., Brady, N., Ali, H., & Biggins, F. (2020) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.308334 · Cited by 1
Nonatherosclerotic Vascular Abnormalities Associated with Chronic Kidney Disease
Mohandas, R., Chamarthi, G., & Segal, M. S. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.012 · Cited by 2
Pathophysiology of Hypertension in Chronic Kidney Disease
Townsend, R. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00021-8 · Cited by 3
Self-citationBiomarkers for Predicting Improved Outcomes With Renal Artery Stenting
Weir, M. R. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.08065
Self-citationDeterminants of Hypertensive Renal Disease and Its Progression
Griffin, K. A., Polichnowski, A. J., & BIDANI, A. K. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-59918-2_27
Behind the Mask: A Call for 24-Hour Blood Pressure Monitoring in Chronic Kidney Disease
Ruzicka, M., & Hiremath, S. S. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11681
Is chronic kidney disease keeping the heart up all night?
Shen, J. I., & Norris, K. C. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13439
Maked hypertension - what we know about this disease
Pokorná, L. Š. M. S. O. M. T., Sovová, E., Masný, O., Pokorná, T., & Sovová, E. (2018) · Medicína pro praxi · doi:10.36290/med.2018.016
Chernatska, O. M., Prystupa, L. N., Fadieieva, H. A., Liashenko, A. V., Погорєлова, О. С., & Ополонська, Н. О. (2021) · Wiadomości Lekarskie · doi:10.36740/wlek202105127
Molecular aspects of the altered Angiotensin II signaling in Gitelman’s syndrome
Ravarotto, V., Bertoldi, G., Stefanelli, L. F., Gobbi, L., & Calò, L. A. (2022) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2022.2066996
Cha, R., & Kim, S. G. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001329
Why take organ damage in hypertension seriously?
Kociánová, E. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.064
Hiremath, S. S. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch22
Paes, F. J. V. N., Albuquerque, F. D. A., Maciel, V. F., de Abreu, J. S., Costa, S. D., Esmeraldo, R. D. M., & de Sandes‐Freitas, T. V. (2022) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v25i4.487_in
Tirmenštajn‐Janković, B., & Bastać, D. (2022) · Timocki medicinski glasnik · doi:10.5937/tmg2202084t
Paes, F. J. V. N., Albuquerque, F. D. A., Maciel, V. F., de Abreu, J. S., Costa, S. D., Esmeraldo, R. D. M., & de Sandes‐Freitas, T. V. (2022) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v25i4.487_esp
Paes, F. J. V. N., Albuquerque, F. D. A., Maciel, V. F., de Abreu, J. S., Costa, S. D., Esmeraldo, R. D. M., & de Sandes‐Freitas, T. V. (2022) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v25i4.487_pt
Katsagoni, C. N., Kokkinos, P. F., & Sidossis, L. S. (2023) · Wiley eBooks · doi:10.1002/9781119833475.ch16
dos Santos, J., Meira, K. C., Coelho, J. C., & Pierin, Â. M. G. (2023) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.16n.6-017
Jhee, J. H., & Park, S. (2024) · Hypertension Research · doi:10.1038/s41440-024-01825-1
“Previous study by Drawz et al. using the CRIC cohort has shown that masked hypertension is associated with poor target organ damage, which is prominent in elevated nocturnal BP in CKD patients [17].”
Recent Advances in Therapeutic Approach for Hypertension to Improve Cardiac Health
Akhter, M. S., & Ahmad, Q. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.111841 · Cited by 3
Blood Pressure: The Interactions Between Hypertension and Kidney Disease
Rayner, H. C., Thomas, M. E., Dasgupta, I., Lalayiannis, A. D., & Hameed, M. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-66349-9_12
Social Determinants of Health and Nocturnal Hypertension in the Chronic Renal Insufficiency Cohort
Byfield, R. L., Cohen, D. L., Drawz, P. E., Kronish, I. M., Shimbo, D., Cohen, J. B., Anderson, A. H., Appel, L. J., Chen, J., Dember, L. M., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.11.008
Self-citationMcEvoy, J. W., McCarthy, C. P., Brouwers, S., & Others, A. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.372 · Cited by 2
Ураження нирок при артеріальній гіпертензії (діагностичні й терапевтичні аспекти)
Koval, S. M., Рєзнік, Л. А., Старченко, Т. Г., & Литвинова, О. М. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.369 · Cited by 1
Treatment of early hypertensive renal damage with Quanduzhong capsules: two case reports
Zhang, G., Fan, J.-R., Wang, Z., He, Q., Gao, X., Li, X., Zhou, Z., Cui, Y., & Li, L. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000003966
“Hypertension is the top risk factor for chronic kidney disease and end-stage renal disease [3].”
Asgedom, D. K., Abuhay, H. W., & Gezie, L. D. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334428 · Cited by 1
Wen, R.-W., Chen, X.-Q., Zhu, Y., 柯剑婷, Du, Y., Wang, C., & Lou, T.-Q. (2020) · Figshare · doi:10.6084/m9.figshare.13467193
Wang, Q., Wang, Y., Wang, J., Zhang, L., & Zhao, M. (2020) · Figshare · doi:10.6084/m9.figshare.12487538
Xie, Z., Zhang, J., Wang, C., & Yan, X. (2021) · Figshare · doi:10.6084/m9.figshare.14736915
Hypertension: A Proximal Clinical Signature and Promoter of Early Cardiorenal Disease?
Bachlitzanaki, M., Aletras, G., Papakonstantinopoulou, K., Vasilaki, N., Bachlitzanaki, E., Stratinaki, M., & Lydakis, C. (2026) · Journal of CardioRenal Medicine · doi:10.3390/jcrm2010002
Chen, C., Deng, R. Z., Ju, M., Ge, S., Yu, W., Song, Q., Tang, Y., Li, Q., Li, M., & Wang, C. (2026) · Hypertension Research · doi:10.1038/s41440-026-02576-x
Predicting Nocturnal Hypertension in CKD Through Table-Value Diffusion Model
Cai, X., Li, R., Liu, Z., Liu, S. H., Zhang, X., Jiang, X., Ge, S., Zhang, J. W., Li, M., Peng, H., et al. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.26706
Masked Nocturnal Hypertension and Hidden Organ Risk: A Systematic Review
Berro, A. M., Alla, M. M. O., Madani, M., Elkhair, R. E., Musa, E., Ahourani, M. M., & Ahmed, A. (2026) · Cureus · doi:10.7759/cureus.111479
A Comprehensive Review on the Efficacy of Antihypertensives in Patients With End‐Stage Renal Disease
AKELE, O., Asogwa, N., Makhoul, G. W., Gharib, K. E., Ling, J., Agarwal, A., Agberien, V. O.-O., Pokima, N., Gut, T., & El‐Sayegh, S. (2026) · International Journal of Hypertension · doi:10.1155/ijhy/9930482
“The optimal therapeutic strategy in this population requires careful consideration of efcacy, safety, drug interactions, and potential adverse efects [30].”
Karagiannidis, A. G., Theodorakopoulou, M. P., Iatridi, F., & Sarafidis, P. A. (2026) · The Nephron journals/Nephron journals · doi:10.1159/nef/adtag007
Yu, J., Yu, J., Yang, R., Qiu, Y., Li, J., Yang, X., Chen, W., Xia, X., & Liu, Q. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187300
“Masked hypertension affects 19.3% to nearly 30% of PD patients [5,6]; although their target organ damage is comparable to that of sustained hypertension [7], their CV risk is routinely underestimated due to normal office BP values.”
InfluentialKomilova, B. I., Demyanova, K. A., Kozlovskaya, N. L., Олеговна, К. Е., Zhdanova, T. V., & Kobalava, Z. D. (2026) · Nephrology and Dialysis · doi:10.28996/2618-9801-2026-3-377-387
Zhang, Z., Dong, X., Ding, X., Jiang, W., & Fang, Y. (2026) · Journal of Clinical Hypertension · doi:10.1111/jch.70378
Metadata
- Authors
- Drawz, P. E., Alper, A. B., Anderson, A. H., Brecklin, C. S., Charleston, J., Chen, J., Deo, R., Fischer, M. J., He, J., Hsu, C.-Y., Huan, Y., Keane, M. G., Kusek, J. W., Makos, G. K., Miller, E. R., Soliman, E. Z., Steigerwalt, S. P., Taliercio, J. J., Townsend, R. R., Weir, M. R., Wright, J. T., Xie, D., & Rahman, M.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Drawz, Paul E.
- ORCID
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2016-04
- Volume
- 11
- Issue
- 4
- Pages
- 642-652
- ISSN
- 1555-9041 (ISSN-L)
- PMC
- PMC4822674
- OpenAlex
- W2278752373
- Cited by
- 199
- References
- 47
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 15 · 2023: 13 · 2022: 23 · 2021: 20 · 2020: 31 · 2019: 28 · 2018: 23 · 2017: 13 · 2016: 8
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Society of Nephrology
- National Institutes of Health (UL1TR000114, UL1TR000433, 5k23dk087919-05, UL1TR000424, UL1TR000003, UL1TR000439)
- National Institute of General Medical Sciences (P30GM103337)
- National Institute of Diabetes and Digestive and Kidney Diseases (K23-DK087919, K01DK092353, U01DK060990, DK 067390, R01DK067390, R01DK139225, U01DK060984, U01DK060902, U01DK060980, U01DK061022, U01DK060963, U01DK061021, U01DK061028)
- National Center for Research Resources (UL1RR024131, M01RR016500, UL1RR029879)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- masked hypertension, nocturnal blood pressure, chronic kidney disease, white coat hypertension, sustained hypertension, estimated glomerular filtration rate, proteinuria, left ventricular mass, pulse wave velocity, ambulatory blood pressure monitoring, hypertension control, Chronic Renal Insufficiency Cohort Study, cardiovascular risk stratification, cardiovascular risk reclassification
- MeSH terms
- Aged, Cardiovascular Diseases, Cross-Sectional Studies, Female, Humans, Kidney Diseases, Male, Middle Aged, Cohort Studies, Prevalence, Renal Insufficiency, Chronic, Masked Hypertension
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.